Atlas Trials

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Clinical trial NCT04421378 · TERMINATED

Trial details

NCT number
NCT04421378
Sponsor
Karyopharm Therapeutics Inc
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Glioblastoma Multiforme
Start date
2020-06-08
Primary completion
2023-07-03
Enrollment
74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.